The mechanistic rationale of aspirin plus FOLFOX sequential combination therapy in suppressing BIRC7/Livin and reactivating DARC and PD-L1 expression underscores the potential of aspirin combination therapy in future CRC management. The gene discussed is BIRC7; the disease is colorectal carcinoma.